Navigation Links
Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer
Date:5/20/2013

we are merging novel pharmacology with local, sustained delivery of drug to the site of disease – an approach that aims to ensure lasting therapeutic effect and systemic safety. We are currently advancing a portfolio of best-in-class drug candidates that have the potential to treat mild, moderate and severe forms of osteoarthritis. Top-line data for FX005, an intra-articular sustained release p38 MAP kinase inhibitor and our lead compound, showed prolonged improvement in joint pain and function throughout the 12-week duration of the Phase 2 study. FX006, an intra-articular sustained release steroid, is currently being evaluated in a Phase 2b dose-ranging study with data expected in the middle of 2013. FX007, an intra-articular sustained release TrkA inhibitor, is being developed to safely address the intractable pain associated with end-stage osteoarthritis.

For more information please visit www.flexiontherapeutics.com.

Editor's Note: Photograph of Frederick Driscoll available on requestMedia ContactsCorporate ContactTony Russo, Ph.D.Lisa Davidson, MBAMatt Middleman, M.D.Vice President, Finance and AdministrationRusso PartnersT: 781-897-9965T: 212-845-425ldavidson@flexiontherapeutics.comT: 212-845-4272 tony.russo@russopartnersllc.com matt.middleman@russopartnersllc.com 
'/>"/>

SOURCE Flexion Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
3. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
6. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
7. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
8. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
9. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
10. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
11. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... laureate Herbert Kroemer famously observed, referring to the ... where layers of different materials meet. In today,s ... of metal oxides are becoming increasingly prominent, with ... superconductors, ferroelectrics and multiferroics. Realizing the vast potential ...
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... Physicists at the University of Pennsylvania have ... measuring the way it conducts electricity on a ... of graphene, the ultra-thin, single-atom thick carbon sheets ... silicon, the current material of choice for transistor ...
... SOUTH SAN FRANCISCO, Calif., July 31 Poniard,Pharmaceuticals, ... focused,on oncology, today announced that the Company will ... Moores UCSD Cancer Center,Translational Oncology Symposium on Friday, ... Ph.D., director of preclinical and translational medicine,for Poniard ...
... HOUSTON and OTTAWA, July 31 /PRNewswire-FirstCall/ - iNutrition, ... Fission Fruit Bars, its,new all natural line of ... http://www.fissionbars.com, and come in three varieties; Fission ... Featuring morsels of,real, delicious fruits, Fission Bars have ...
Cached Biology Technology:Penn scientists demonstrate potential of graphene films as next-generation transistors 2Penn scientists demonstrate potential of graphene films as next-generation transistors 3Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium 2iNutrition Launches New Fission Fruit Nutrition Bars 2
(Date:4/23/2014)... RICHLAND, Wash. -- Like a hungry diner ripping open ... hydrogen into electricity must tear open a hydrogen molecule. ... catalyst holding onto the two halves of its hydrogen ... into how to make the catalyst work better for ... time scientists have shown precisely where the hydrogen halves ...
(Date:4/23/2014)... French and Spanish . ... CEC released its Conservation Assessment for the Big Bend-Ro ... identifies 29 priority conservation areas in a region straddling ... areas in the states of Texas, Coahuila, and Chihuahua. ... habitats inhabited by rare and endangered plants and animals, ...
(Date:4/23/2014)... (Apr. 23 2014) A team of ... cells (hNSCs) into the brains of nonhuman primates ... and 24 months found that the hNSCs had ... not cause tumors. , The study will be ... Transplantation but is currently freely available on-line ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2
... resistance of potatoes to late blight, their most important ... by the Biotechnology and Biological Sciences Research Council and ... Transactions of the Royal Society B , on 17 ... trial, the potatoes experienced ideal conditions for late blight. ...
... dividing to maintain our body functions. At each division, our ... to be faithfully duplicated to maintain the cell,s memory of ... developed a new technology that has revealed the dynamic events ... The results are published in Nature Cell Biology . ...
... power of regenerative medicine now allows scientists to transform ... pancreas cells and even neurons. However, a method to ... life-saving therapieshas proven far more difficult. But now, scientists ... San Francisco (UCSF), have made an important breakthrough: they ...
Cached Biology News:GM spuds beat blight 2New technology detect cellular memory 2Scientists transform skin cells into functioning liver cells 2Scientists transform skin cells into functioning liver cells 3
Heavy-duty rim. Especially recommended as a titration flask. Corning5100. capacity 250 mL Special grade: student grade...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Mouse monoclonal [YPF19] to Yersinia pestis F1 antigen ( Abpromise for all tested applications)....
... a new product number, created to ... showing no availability yet, please order ... or contact customer service for assistance. ... 11.25 6.40 in. Mfr ...
Biology Products: